ELA-026 is under clinical development by Electra Therapeutics and currently in Phase I for Hemophagocytic Lymphohistiocytosis. According to GlobalData, Phase I drugs for Hemophagocytic Lymphohistiocytosis have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ELA-026’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ELA-026 overview
ELA-026 is under development for the treatment of secondary hemophagocytic lymphohistiocytosis (sHLH), T cell lymphoma, T cell acute lymphoid leukaemia. It is administered by subcutaneous and intravenous route in the form of solution. It acts by targeting signal regulatory protein-alpha/beta-1/gamma.
It was under development for the treatment of other inflammatory diseases.
Electra Therapeutics overview
Electra Therapeutics is an operator of a biotechnology company that develops monoclonal antibodies designed for the treatment of immunological diseases and cancer. The company is headquartered in San Francisco, California, the US.
For a complete picture of ELA-026’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
